“…Most often it is associated with hematologic disorders, both neoplastic (e.g., myelofibrosis and the spent phase of polycythemia vera [5]) and non-neoplastic (as in thalassemias [6]). It has also been described in association with some tumors, including cerebellar hemangioblastomas (7), hemangiomas (8), hepatoblastomas (9), leiomyomas (10), pilomatricomas (11), hepatic angiosarcoma (12), endometrial carcinoma (13), meningioma (14), hepatic adenoma (15), mesoblastic nephroma (16), liposarcoma (17), myofibroblastic tumors and renal cell carcinomas, and in a variety of non-neoplastic environments such as allograft livers (18,19), acute tubular necrosis (20), breast biopsy cavities (21), endometrial stroma (14), congenital viral infections (22), and a myocardial infarct (23). The pathophysiology of EMH in cases not associated with hematologic disorders seems to be different from EMH in myelofibrosis and the spent phase of polycythemia vera.…”